Success Metrics

Active Trials
2(100%)

Phase Distribution

Ph phase_2
2
100%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

2

all time

Status Distribution
Active(2)

Detailed Status

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 22 (100.0%)

Trials by Status

active_not_recruiting2100%

Recent Activity

2 active trials
Showing 2 of 2
active_not_recruitingphase_2

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446
active_not_recruitingphase_2

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

NCT06924970

Clinical Trials (2)

Showing 2 of 2 trials
NCT05490446Phase 2

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Active Not Recruiting
NCT06924970Phase 2

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Active Not Recruiting

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2